Near Normal Aminotransferase Levels Reported in Alcoholic Cirrhosis Patients
By LabMedica International staff writers Posted on 30 Dec 2021 |

Image: Normal or Near Normal Aminotransferase Levels Found in Patients with Alcoholic Cirrhosis (Photo courtesy of Biology Dictionary)
Alcoholic cirrhosis affects around 1 in 400 adults in the USA. It is an advanced form of liver disease, which occurs when chronic ethanol use leads to inflammation and cirrhosis or scarring of the liver. Less than 50% of people diagnosed with advanced liver disease due to cirrhosis survive for one year, and so early diagnosis is crucial.
Although cirrhosis is generally not a reversible condition, early diagnosis provides physicians with an opportunity to encourage cessation of drinking and offer treatment that can reduce symptoms and increase life expectancy. A common method to diagnose patients with alcoholic cirrhosis is to look for elevated levels of enzymes known as aminotransferases in the liver.
Specialists in Hepatology at the Medical University of South Carolina (Charleston, SC, USA) carried out a retrospective cohort analysis, and identified consecutive patients with documented alcoholic cirrhosis who were admitted between January 1 2016 and December 1 2018. They examined clinical outcomes of 78 patients as a function of whether the aspartate transaminase (AST) or alanine aminotransferase (ALT) was normal or abnormal.
In the cohort of patients with alcoholic cirrhosis (age 55, 26-75; 58% male) 70 had a normal ALT and 12 had a normal AST. The average AST for all patients was 59U/L ± 34U/L (Upper Limit of Normal [ULN] = 35U/L), and the average ALT was 27U/L ± 13U/L (ULN = 45U/L). The average INR was 1.5 ± 0.5 and total bilirubin was 3.7mg/dL ± 4.9mg/dL, and 20 patients had a normal bilirubin level, including only one with an abnormal ALT level. The average model for end-stage liver disease (MELD) score was 19 ± 8 and 32% of patients died during the follow-up time period of five months. Decompensating events were identified in 78 (100%) patients. There was no correlation between complications or death and aminotransferase levels.
Don C. Rockey, MD, a Professor of Medicine and the senior author of the study, said, “We would see these patients with advanced disease and complications, yet their liver tests seemed to be normal. So, if you just looked at their liver tests, you’d say, ‘Oh no problem,’ but in fact, that wasn’t the case.”
The authors concluded that aminotransferase levels are often unremarkable in patients with alcohol related cirrhosis and bear no relationship to clinical events or outcomes. Clinicians should be cautious when interpreting aminotransferases in patients with alcoholic cirrhosis. The study was published on October 4, 2021 in The American Journal of the Medical Sciences.
Related Links:
Medical University of South Carolina
Although cirrhosis is generally not a reversible condition, early diagnosis provides physicians with an opportunity to encourage cessation of drinking and offer treatment that can reduce symptoms and increase life expectancy. A common method to diagnose patients with alcoholic cirrhosis is to look for elevated levels of enzymes known as aminotransferases in the liver.
Specialists in Hepatology at the Medical University of South Carolina (Charleston, SC, USA) carried out a retrospective cohort analysis, and identified consecutive patients with documented alcoholic cirrhosis who were admitted between January 1 2016 and December 1 2018. They examined clinical outcomes of 78 patients as a function of whether the aspartate transaminase (AST) or alanine aminotransferase (ALT) was normal or abnormal.
In the cohort of patients with alcoholic cirrhosis (age 55, 26-75; 58% male) 70 had a normal ALT and 12 had a normal AST. The average AST for all patients was 59U/L ± 34U/L (Upper Limit of Normal [ULN] = 35U/L), and the average ALT was 27U/L ± 13U/L (ULN = 45U/L). The average INR was 1.5 ± 0.5 and total bilirubin was 3.7mg/dL ± 4.9mg/dL, and 20 patients had a normal bilirubin level, including only one with an abnormal ALT level. The average model for end-stage liver disease (MELD) score was 19 ± 8 and 32% of patients died during the follow-up time period of five months. Decompensating events were identified in 78 (100%) patients. There was no correlation between complications or death and aminotransferase levels.
Don C. Rockey, MD, a Professor of Medicine and the senior author of the study, said, “We would see these patients with advanced disease and complications, yet their liver tests seemed to be normal. So, if you just looked at their liver tests, you’d say, ‘Oh no problem,’ but in fact, that wasn’t the case.”
The authors concluded that aminotransferase levels are often unremarkable in patients with alcohol related cirrhosis and bear no relationship to clinical events or outcomes. Clinicians should be cautious when interpreting aminotransferases in patients with alcoholic cirrhosis. The study was published on October 4, 2021 in The American Journal of the Medical Sciences.
Related Links:
Medical University of South Carolina
Latest Pathology News
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
Channels
Molecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more